Abstract
The presented clinical example convincingly demonstrates the efficacy of dydrogesterone (30 mg) in the prevention of severe preeclampsia in a high-risk patient (early development of preeclampsia and preterm Cesarean section in her first pregnancy, arterial hypertension). This case suggests using dydrogesterone as an option to prevent preeclampsia, as previously shown in a prospective randomized study.
Acknowledgments
The authors declare that the article did not have any biomedical financial interests or potential conflicts of interest.
References
1. Cheng MH, Wang PH. Placentation abnormalities in the pathophysiology of preeclampsia. Expert Rev Mol Diagn 2009;9:37–49.10.1586/14737159.9.1.37Search in Google Scholar PubMed
2. Calicchio R, Buffat C, Vaiman D, Miralles F. Endothelial dysfunction: role in the maternal syndrome of preeclampsia and long-term consequences for the cardiovascular system. Ann Cardiol Angeiol (Paris) 2013;62:215–20.10.1016/j.ancard.2013.03.002Search in Google Scholar PubMed
3. Schindler AE. Progestogens for treatment and prevention of pregnancy disorders. Horm Mol Biol Clin Investig 2010;3:453–60.10.1515/hmbci.2010.069Search in Google Scholar
4. Dolgushina VF, Syundukova EG, Sokolov DI, Selkov SA. Soluble intercellular adhesion molecule-1 and endothelin are nonspecific markers of endothelial dysfunction in gestosis. Obstetr Gynecol (Rus) 2015;2:12–9.Search in Google Scholar
5. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;338:701–5.10.1056/NEJM199803123381101Search in Google Scholar PubMed
6. Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. Microcirculation 2014;21:4–14.10.1111/micc.12079Search in Google Scholar PubMed
7. Darmochwal-Kolars D, Kludka-Sternik M. The immunoregulatory disturbances in the pathogenesis of pre-eclampsia. Arch Perinat Med 2010;16:67–73.10.2174/157339510790231815Search in Google Scholar
8. Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol 2015;213(4 Suppl):S115–22.10.1016/j.ajog.2015.08.042Search in Google Scholar PubMed PubMed Central
9. Sukikh GT, Krasnyi AM, Kan NE, Maiorova TD, Tyutyunnik VL, Khovkhaeva PA, Sergunina OA, Tyutyunnik NV, Gracheva MI, Vavina OV, Ozernyuk ND, Boris DA. Placental apoptosis and antioxidant defense enzyme gene expression in preeclampsia. Obstetr Gynecol (Rus) 2015;3:11–15.Search in Google Scholar
10. Beznoshchenko GB, Kravchenko EN, Rogova EV, Liubavina AE, Kuklina LV. Placental insufficiency and the uterine placental area in pregnant women with preeclampsia. Rossiysky vestnik akushera-ginekologa 2014;5:4–8.Search in Google Scholar
11. Furaeva KN, Stepanova OI, Ovchinnikova OM, Vyzmina LP, Bazhenov DO, Kapustin RV, Kramareva NL, Selkov SA, Sokolov DI. Proliferative and migratory activity of trophoblast cells in preeclampsia. Obstetr Gynecol (Rus) 2015;5:49–55.Search in Google Scholar
12. Jabeen M, Yakoob MY, Imdad A, Bhutta ZA. Impact of interventions to prevent and manage preeclampsia and eclampsia on stillbirths. BMC Public Health 2011;11(Suppl 3):S6.10.1186/1471-2458-11-S3-S6Search in Google Scholar PubMed PubMed Central
13. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008; Iss. 2. Art. No.: CD003511. DOI: 10.1002/14651858.CD003511.pub2.Search in Google Scholar PubMed
14. Meher S, Duley L. Progesterone for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2006; Iss. 4. Art. No.: CD006175. DOI: 10.1002/14651858.CD006175Search in Google Scholar PubMed PubMed Central
15. Kiprono LV, Wallace K, Moseley J, Martin J Jr, Lamarca B. Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemia. Am J Obstet Gynecol 2013;209:44.e1–6.10.1016/j.ajog.2013.03.032Search in Google Scholar PubMed PubMed Central
16. Sammour MB, el-Kabarity H, Fawzy MM, Schindler AE. Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens. J Steroid Biochem Mol Biol 2005;97:439–40.10.1016/j.jsbmb.2005.08.014Search in Google Scholar PubMed
17. Zainul Rashid MR, Lim JF, Nawawi NH, Luqman M, Zolkeplai MF, Rangkuty HS, Mohamad Nor NA, Tamil A, Shah SA, Tham SW, Schindler AE. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. J Gynecol Endocrinol 2014;30:217–20.10.3109/09513590.2013.860960Search in Google Scholar PubMed
18. Abalos E1, Duley L, Steyn DW. Antihypertensive drug therapy from mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014;2:CD002252.10.1002/14651858.CD002252.pub3Search in Google Scholar PubMed
19. Xie RH, Guo Y, Krewski D, Mattison D, Walker MC, Nerenberg K, Wen SW. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol 2014;175:124–8.10.1016/j.ejogrb.2014.01.019Search in Google Scholar PubMed
20. Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Gafni A, Gruslin A, Helewa M, Hutton E, Koren G, Lee SK, Logan AG, Ganzevoort JW, Welch R, Thornton JG, Moutquin J-M. Control of hypertension in pregnancy study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG 2016;123:1135–41.10.1111/1471-0528.13568Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
